Morningstar maintains fair value estimates on Aussie health firms despite Trump's 200% tariffs plan

Fisher & Paykel Healthcare

09/07/2025 21:04

** Analysts at Morningstar maintain fair value estimates on Australian health companies, anticipating a change in U.S. President Donald Trump's position on pharmaceutical tariffs

** Trump said on Tuesday he plans to announce tariffs on imported pharmaceuticals to the U.S. which could reach 200%

** Investment research firm sees CSL CSL.AX being impacted by the tariffs as it processes some U.S. products in Australia, but doesn't expect earnings to take a material hit

** "Tariffs this high are unlikely to persist and CSL can adapt by onshoring manufacturing" - Morningstar

** Also anticipates Ansell ANN.AX, Polynovo PNV.AX, Nanosonics NAN.AX, and Fisher & Paykel FPH.NZ to be impacted, if tariffs come into effect

** Says Telix TLX.AX is enviably exempt from all potential tariffs on pharmaceuticals though shares remain overvalued

  Morningstar Fair Value Estimates -

Stock
Fair Value Estimates
CSL Ltd
A$325
Fisher & Paykel Healthcare
A$25
Ansell
A$36.50
Telix Pharmaceuticals
A$19.50
Nanosonics
A$4.30
Polynovo
A$1.15

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)

 ((JasmeenAraIslam.Shaikh@thomsonreuters.com;))